Drug Trial Radar · NCT04180150
A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B
Last checked: Nov 19, 2026Latest source record: Dec 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
12
Planned (sponsor's estimate)
Start
Nov 18, 2019
Primary completion
Sep 30, 2020
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blinded, placebo-controlled, phase IIa study to evaluate safety and efficacy of TQ-A3334 combined with entecavir in the untreated or HBV DNA negative subjects with Chronic Hepatitis B.
Conditions
- Chronic Hepatitis B
Interventions
TQ-A3334Drug
TQ-A3334 is a kind of TLR7 receptor agonist.
PlaceboDrug
Placebo is a treatment which is designed to have no therapeutic value.
Entecavir TabletDrug
Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.
- TmaxTime frame: Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.
- AUC0-tTime frame: Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.
- CytokineTime frame: Hour 0, 1.5 , 12 , 24 , 72 hours post-dose at week 1 and week 12; Hour 0 at week 7.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The second affiliated hospital of chongqing medical university
Chongqing, Chongqing Municipality, China · Not yet recruiting
The first hospital of Jilin University
Changchun, Jinlin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.